Investigation of regional mechanisms responsible for poor oral absorption in humans of a modified release preparation of the alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003): the rational use of ex vivo intestine to predict in vivo absorption.

Modified release (MR) formulations are used to enhance the safety and compliance of existing drugs by improving their pharmacokinetics. Predicting the likely success of MR formulations is often difficult before clinical studies. A systematic in vitro approach using mouse and human tissues was adopted to rationalize the in vivo pharmacokinetics of 9- and 15-h MR formulations of an alpha-adrenoreceptor antagonist, 4-amino-6,7-dimethoxy-2-(5-methanesulfonamido-1,2,3,4 tetrahydroisoquinol-2-yl)-5-(2-pyridyl)quinazoline (UK-338,003).

Treatment of central venous catheter occlusions with ethanol and hydrochloric acid.

Background: Occluded central venous lines (CVLs) is a major problem in pediatric patients.

Methods: To relieve obstructed catheters, infusions of ethanol (up to 3 mL of a 70% solution) for presumed lipid occlusions and hydrochloric acid (HCl, 0.1 N, up to 3 mL) for presumed mineral and drug precipitates were given in an attempt to relieve obstructed catheters.